Multiple Sclerosis Drugs Market By Drug Class (Immunomodulators, Immunosuppressants, Interferons & Others), By Route Of Administration (Oral, Injection (Intramuscular, Subcutaneous & Intravenous)), By Geography - Global Opportunity Analysis & Industry Forecast, 2023-2028

Report Code: HCR 0322 Report Format: PDF + Excel

Multiple Sclerosis Drugs Market Overview

The Multiple Sclerosis Drugs Market size is estimated to reach $31.3 billion by 2028, growing at a CAGR of 3.7% during the forecast period 2023-2028. Treatment of multiple sclerosis may involve immunosuppressants, immunomodulators and monoclonal antibodies. Interferons are disease-modifying drugs that assist in decreasing relapses in people enduring multiple sclerosis. Intramuscular injections are utilized when additional kinds of delivery techniques like oral, intravenous and subcutaneous are not suggested. As per a novel clinical trial in August 2022, an experimental antibody therapy for multiple sclerosis can reduce symptom flare-ups by half, as compared to standard treatment. Interferon beta-1a has been certified by the U.S. Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis and it has been assessed in clinical trials for the treatment of COVID-19. According to the National Multiple Sclerosis Society, more than 2.8 million people are living with Multiple Sclerosis worldwide. The burgeoning focus of firms on pipeline products for multiple sclerosis is set to drive the Multiple Sclerosis Drugs Market. The recommended continuous medicines for multiple sclerosis-like interferons to decrease the requirement for hospitalization due to COVID-19 are set to propel the growth of the Multiple Sclerosis Drugs Industry during the forecast period 2023-2028. This represents the Multiple Sclerosis Drugs Industry Outlook.

Multiple Sclerosis Drugs Market Report Coverage

The Multiple Sclerosis Drugs Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Multiple Sclerosis Drugs Market.

By Drug Class: Immunomodulators, Immunosuppressants, Interferons and Others.
By Route Of Administration: Oral, Injection (Intramuscular, Subcutaneous and Intravenous).
By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America (Multiple Sclerosis Drugs market share) accounted for the highest revenue share in 2022. It is poised to dominate the market over the period 2023-2028 owing to the increasing predominance of multiple sclerosis involving immunomodulators in the North American region.
  • The growth of the Multiple Sclerosis Drugs Market is being driven by considerable financing of large pharmaceutical firms in the drug development procedure and surging interferon treatment of Multiple Sclerosis. However, the soaring cost of medications is one of the major factors hampering the growth of the Multiple Sclerosis Drugs Market.
  • The Multiple Sclerosis Drugs Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Multiple Sclerosis Drugs Market report.

Multiple Sclerosis Drugs Market: Market Share (%) by Region, 2022
Multiple Sclerosis Drugs Market
For More Details on This Report - Request for Sample

Multiple Sclerosis Drugs Market Segment Analysis - by Drug Class

The Multiple Sclerosis Drugs Market based on drug class can be further segmented into Immunomodulators, Immunosuppressants, Interferons and Others. The Immunomodulators Segment held the largest share of the Multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging application of immunomodulators for the treatment of multiple sclerosis and its connected symptoms. Interferon beta and glatiramer acetate (GA) were the earliest immunomodulators certified for the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. The greater prescription rates are further propelling the growth of the Immunomodulators segment.

Furthermore, the Immunosuppressants segment is estimated to grow at the fastest CAGR of 4.3% during the forecast period 2023-2028 owing to the typical application of immunosuppressants like azathioprine, cyclophosphamide, methotrexate and mitoxantrone for the treatment of Multiple Sclerosis as well as application of immunosuppressants as combination therapy or monotherapy.

Multiple Sclerosis Drugs Market Segment Analysis - by Route Of Administration

The Multiple Sclerosis Drugs Market based on the route of administration can be further segmented into Oral, Subcutaneous and Injection. The Injection Segment held the largest share of the multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging count of approvals for multiple sclerosis medications as injections for subcutaneous application in the treatment of ailment. The injection segment is sub-segmented into intramuscular, subcutaneous and intravenous. The increasing application of intravenous (IV) infusions like OCREVUS to treat relapsing or primary progressive forms of Multiple Sclerosis is further propelling the growth of this segment.

Furthermore, the Oral segment is estimated to grow at the fastest CAGR of 5.5% during the forecast period 2023-2028 due to the growing introduction of novel products, assistance in patient satisfaction, boosting therapeutic compliance and the soaring inclination toward oral medications.

Multiple Sclerosis Drugs Market Segment Analysis - by Geography

North America (Multiple Sclerosis Drugs Market) dominated the Multiple Sclerosis Drugs market with a 40% share of the overall market in 2022. The growth is driven by the existence of key players in the North American region. The approval by regulatory authorities is further propelling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fuelled by the factors like enhanced distribution networks of pharmaceutical firms in emerging economies in the Asia-Pacific region. The surging government initiatives are further fueling the progress of the Multiple Sclerosis Drugs Market in the Asia-Pacific region.

Multiple Sclerosis Drugs Market Drivers

Surging Approvals for Intramuscular Injections:

As per Healthline, current findings from the National MS Society estimate that almost 1 million people in the U.S. are living with Multiple Sclerosis. In February 2021, the U.S. Food and Drug Administration (FDA) certified an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat patients with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into the muscle, is what is usually utilized to convey the flu shot. As per Biogen, Plegridy’s developer, treatment provided through intramuscular injection is as efficient as the subcutaneous injection formulation. This novel formulation was also currently certified by the European Commission. The surging approvals for intramuscular injections are therefore fueling the growth of the Multiple Sclerosis Drugs Market during the forecast period 2023-2028.

Soaring Treatment Involving Immunomodulators and Immunosuppressants:

As per Healthline, a supposed 2.5 million people live with Multiple Sclerosis globally. Medications certified for application in multiple sclerosis that decrease the frequency of intensifications or gradual infirmity advancement are termed disease-modifying drugs (DMDs). These DMDs can be further categorized as immunomodulators or immunosuppressants. Teriflunomide is an oral immunomodulator that causes anti-inflammatory impacts by restricting dihydroorotate dehydrogenase, a mitochondrial enzyme included in pyrimidine synthesis. It is designated for relapsing forms of MS. The most typically utilized immunosuppressants in Multiple Sclerosis are azathioprine, cyclophosphamide, methotrexate and mitoxantrone. The soaring treatment involving immunomodulators and immunosuppressants is fueling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook during the forecast period 2023-2028.

Multiple Sclerosis Drugs Market Challenges

Side Effects of Interferons:

As per MS Discovery Forum, an approximated 200 novel cases are diagnosed every week in the U.S. Interferon beta (IFNbeta) decreases the relapse rate and activity as assessed by serial MRI scanning and ailment advancement of Multiple Sclerosis. Therapy with IFNbeta may be connected with numerous unfavorable reactions. Comparatively repeated side effects involve flu-like symptoms, transient laboratory abnormalities, menstrual ailments and raised spasticity. Dermal injection site reactions happen subsequent to subcutaneous application of IFNbeta-1b and IFNbeta-1a. Likely side effects of IFNbeta involve different autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia and depression. These issues are thus hampering the growth of the Multiple Sclerosis Drugs Market.

Multiple Sclerosis Drugs Industry Outlook

More focus on pipeline drugs for multiple sclerosis and emerging R&D financing in the pharmaceutical industry are key strategies adopted by players in the Multiple Sclerosis Drugs Market. The top 10 companies in the Multiple Sclerosis Drugs market are:

  1. Bayer AG
  2. Teva Pharmaceutical Industries Ltd.
  3. Novartis AG
  4. Sanofi Inc.
  5. F. Hoffmann-La Roche Ltd.
  6. Celgene Corporation
  7. Acorda Therapeutics, Inc.
  8. Biogen, Inc.
  9. Actelion Pharmaceuticals Ltd. (Johnson & Johnson)
  10. Merck Serono (Merger between EMD Serono and Merck KGaA)

Recent Developments

  • In October 2021, Novartis declared that it would introduce 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The data being introduced covered an all-inclusive MS portfolio. This stressed the firm’s dedication in enhancing the quality of life for people residing with MS at all phases of the ailment.
  • In June 2021, Novartis marked a collaboration agreement and alternative to acquiring Cellerys. Cellerys is a Zurich-based startup, conducting research on a therapy to combat Multiple Sclerosis (MS). 
  • In January 2020, Novartis favorably finished the acquisition of The Medicines Company. This included a possibly first-in-class, investigational cholesterol-lowering therapy - inclisiran. The Medicines Company proposed the New Drug Application (NDA) for inclisiran to FDA in December 2019. 

Relevant Reports:

Primary Progressive Multiple Sclerosis Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0268

Interferon Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0228

Autoimmune Drugs & Disease Management Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0961

For more Lifesciences and Healthcare Market reports, please click here

1. Multiple Sclerosis Drugs Market Overview
    1.1 Definitions and Scope
2. Multiple Sclerosis Drugs Market - Executive Summary
3. Multiple Sclerosis Drugs Market – Market Landscape
    3.1 Company Benchmarking - Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Multiple Sclerosis Drugs Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Multiple Sclerosis Drugs Market – Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Multiple Sclerosis Drugs Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porter's five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Multiple Sclerosis Drugs Market – Strategic Analysis
    7.1 Value Chain Analysis 
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Multiple Sclerosis Drugs Market – by Drug Class (Market Size – $Million/$Billion) 
    8.1 Immunomodulators
    8.2 Immunosuppressants
    8.3 Interferons
    8.4 Others
9. Multiple Sclerosis Drugs Market – by Route Of Administration (Market Size – $Million/$Billion) 
    9.1 Oral
    9.2 Injection
        9.2.1 Intramuscular
        9.2.2 Subcutaneous
        9.2.3 Intravenous
10. Multiple Sclerosis Drugs Market - by Geography (Market Size - $Million/Billion)
    10.1 North America
        10.1.1 The US
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 The UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 The Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 The Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 The Rest of South America
    10.5 The Rest of the World
        10.5.1 The Middle East
        10.5.2 Africa
11. Multiple Sclerosis Drugs Market - Market Entropy
    11.1 New product launches
    11.2 M&As, collaborations, JVs and partnerships
12. Multiple Sclerosis Drugs Market – Industry Competition Landscape (Premium)
    12.1 Market Share by Region – Key Companies
        12.1.1 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Multiple Sclerosis Drugs Market – Key Company List by Country Premium (Premium)
14. Multiple Sclerosis Drugs Market - Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
* "Financials would be provided to private companies on best-efforts basis." 
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.
List of Tables:

Table 1: Multiple Sclerosis Drugs Market Overview 2021-2026
Table 2: Multiple Sclerosis Drugs Market Leader Analysis 2018-2019 (US$)
Table 3: Multiple Sclerosis Drugs Market Product Analysis 2018-2019 (US$)
Table 4: Multiple Sclerosis Drugs Market End User Analysis 2018-2019 (US$)
Table 5: Multiple Sclerosis Drugs Market Patent Analysis 2013-2018* (US$)
Table 6: Multiple Sclerosis Drugs Market Financial Analysis 2018-2019 (US$)
Table 7: Multiple Sclerosis Drugs Market Driver Analysis 2018-2019 (US$)
Table 8: Multiple Sclerosis Drugs Market Challenges Analysis 2018-2019 (US$)
Table 9: Multiple Sclerosis Drugs Market Constraint Analysis 2018-2019 (US$)
Table 10: Multiple Sclerosis Drugs Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Multiple Sclerosis Drugs Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Multiple Sclerosis Drugs Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Multiple Sclerosis Drugs Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Multiple Sclerosis Drugs Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Multiple Sclerosis Drugs Market Value Chain Analysis 2018-2019 (US$)
Table 16: Multiple Sclerosis Drugs Market Pricing Analysis 2021-2026 (US$)
Table 17: Multiple Sclerosis Drugs Market Opportunities Analysis 2021-2026 (US$)
Table 18: Multiple Sclerosis Drugs Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Multiple Sclerosis Drugs Market Supplier Analysis 2018-2019 (US$)
Table 20: Multiple Sclerosis Drugs Market Distributor Analysis 2018-2019 (US$)
Table 21: Multiple Sclerosis Drugs Market Trend Analysis 2018-2019 (US$)
Table 22: Multiple Sclerosis Drugs Market Size 2018 (US$)
Table 23: Multiple Sclerosis Drugs Market Forecast Analysis 2021-2026 (US$)
Table 24: Multiple Sclerosis Drugs Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 26: Multiple Sclerosis Drugs Market By Product Type, Revenue & Volume,By Immunomodulators, 2021-2026 ($)
Table 27: Multiple Sclerosis Drugs Market By Product Type, Revenue & Volume,By Immunosuppressant, 2021-2026 ($)
Table 28: Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 29: Multiple Sclerosis Drugs Market By Administration, Revenue & Volume,By InjecTable, 2021-2026 ($)
Table 30: Multiple Sclerosis Drugs Market By Administration, Revenue & Volume,By Infused, 2021-2026 ($)
Table 31: Multiple Sclerosis Drugs Market By Administration, Revenue & Volume,By Oral, 2021-2026 ($)
Table 32: North America Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 33: North America Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 34: South america Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 35: South america Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 36: Europe Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 37: Europe Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 38: APAC Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 39: APAC Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 40: Middle East & Africa Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 41: Middle East & Africa Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 42: Russia Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 43: Russia Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 44: Israel Multiple Sclerosis Drugs Market, Revenue & Volume,By Product Type, 2021-2026 ($)
Table 45: Israel Multiple Sclerosis Drugs Market, Revenue & Volume,By Administration, 2021-2026 ($)
Table 46: Top Companies 2018 (US$)Multiple Sclerosis Drugs Market, Revenue & Volume
Table 47: Product Launch 2018-2019Multiple Sclerosis Drugs Market, Revenue & Volume
Table 48: Mergers & Acquistions 2018-2019Multiple Sclerosis Drugs Market, Revenue & Volume


List of Figures:

Figure 1: Overview of Multiple Sclerosis Drugs Market 2021-2026
Figure 2: Market Share Analysis for Multiple Sclerosis Drugs Market 2018 (US$)
Figure 3: Product Comparison in Multiple Sclerosis Drugs Market 2018-2019 (US$)
Figure 4: End User Profile for Multiple Sclerosis Drugs Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Multiple Sclerosis Drugs Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Multiple Sclerosis Drugs Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Multiple Sclerosis Drugs Market 2018-2019
Figure 8: Ecosystem Analysis in Multiple Sclerosis Drugs Market 2018
Figure 9: Average Selling Price in Multiple Sclerosis Drugs Market 2021-2026
Figure 10: Top Opportunites in Multiple Sclerosis Drugs Market 2018-2019
Figure 11: Market Life Cycle Analysis in Multiple Sclerosis Drugs Market
Figure 12: GlobalBy Product TypeMultiple Sclerosis Drugs Market Revenue, 2021-2026 ($)
Figure 13: GlobalBy Administration Multiple Sclerosis Drugs Market Revenue, 2021-2026 ($)
Figure 14: Global Multiple Sclerosis Drugs Market - By Geography
Figure 15: Global Multiple Sclerosis Drugs Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 16: Global Multiple Sclerosis Drugs Market CAGR, By Geography, 2021-2026 (%)
Figure 17: North America Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 18: US Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 60: U.K Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 93: China Multiple Sclerosis Drugs Market Value & Volume, 2021-2026
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($)Multiple Sclerosis Drugs Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Multiple Sclerosis Drugs Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 122: Russia Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Multiple Sclerosis Drugs Market Value & Volume, 2021-2026 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%)Multiple Sclerosis Drugs Market
Figure 131: Developments, 2018-2019*Multiple Sclerosis Drugs Market
Figure 132: Company 1 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Multiple Sclerosis Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Multiple Sclerosis Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Multiple Sclerosis Drugs Market Net Sales Share, By Geography, 2018 (%)